Table 3.

Qualifying therapies among subjects who developed WHF^*.

Therapy	DOSE N=72	ROSE N=22
IV vasoactive agent	9 (12.5%)	20 (90.9%)
Mechanical or circulatory support	0 (0%)	0 (0%)
Ultra-filtration	0 (0%)	1 (4.5%)
Loop diuretic, thiazide or metolazone	65 (90.3%)	N/A

WHF indicates worsening heart failure; ROSE, Renal Optimization Strategies; DOSE, Diuretic Optimization Strategies Evaluation; n, number; IV, intravenous

^*WHF was reported on the case report form with qualifying therapies listed below. The specific qualifying therapy was listed below with the option to select (or not) one or more qualifying therapies.